Genetic changes required for the formation and progression of human Schwann cell tumors remain elusive. Using a Sleeping Beauty forward genetic screen, we identifi ed several genes involved in canonical Wnt signaling as potential drivers of benign neurofi bromas and malignant peripheral nerve sheath tumors (MPNSTs). In human neurofi bromas and MPNSTs, activation of Wnt signaling increased with tumor grade and was associated with downregulation of β-catenin destruction complex members or overexpression of a ligand that potentiates Wnt signaling, R-spondin 2 ( RSPO2 ). Induction of Wnt signaling was suffi cient to induce transformed properties in immortalized human Schwann cells, and downregulation of this pathway was suffi cient to reduce the tumorigenic phenotype of human MPNST cell lines. Small-molecule inhibition of Wnt signaling effectively reduced the viability of MPNST cell lines and synergistically induced apoptosis when combined with an mTOR inhibitor, RAD-001, suggesting that Wnt inhibition represents a novel target for therapeutic intervention in Schwann cell tumors.
INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that are believed to originate in the Schwann cell or Schwann cell precursors ( 1 ) . These tumors can occur in the context of Neurofi bromatosis Type 1 syndrome (NF1), which occurs in 1 in 3,000 live births, but can also occur spontaneously in the general population ( 2, 3 ) . Because of the incomplete understanding of the genes and pathways driving MPNST development and progression, the current treatment for patients is surgical resection of the tumor, if possible, followed by nonspecifi c, high-dose chemotherapy ( 4, 5 ) . These therapies often prove ineffective, and subsequently, patients with MPNSTs suffer very poor 5-year survival rates of less than 25% ( 3, 4 ) . This shows the urgent need for a more complete understanding of the genetic events that drive these tumors, to develop novel targeted therapies to treat these patients.
It is known that biallelic loss of the Neurofi bromin 1 gene ( NF1 ) in Schwann cells is the pathologic cause of the benign neurofi bromas seen in NF1 patients, but secondary genetic changes, many of which remain unknown, must occur for these benign tumors to transform into MPNSTs ( 1 , 5-8 ) . Ten percent of NF1-associated neurofi bromas will undergo malignant transformation, the leading cause of death in adult NF1 patients ( 4, 5 ) . MPNSTs can also form spontaneously, in the absence of NF1 loss, and the genes responsible for spontaneous MPNST formation are also largely unknown ( 3, 4 ) . Loss of PTEN expression and overexpression of EGF receptor (EGFR) are 2 changes often seen in both spontaneous MPNSTs and NF1-associated MPNSTs, but there are likely many other important genetic changes and signaling pathways yet to be identifi ed ( 5 , 8-14 ) .
Canonical Wnt/β-catenin signaling has been shown to play a role in many types of cancer, including colorectal, lung, breast, ovarian, prostate, liver, and brain tumors ( 15 ) . However, this pathway has not been directly implicated in neurofi bromas or MPNSTs. In other cell types, Wnt signaling can be activated in cancer through a variety of mechanisms, including activating mutations in β-catenin ( CTNNB1 ), overexpression of Wnt ligand genes, inactivating mutations in AXIN1 , GSK3B , and APC (all encoding members of the β-catenin destruction complex), and promoter hypermethylation of negative regulators of Wnt signaling ( 16 ) . Another mechanism of Wnt pathway activation recently shown in colorectal cancer is overexpression of R-spondins due to gene fusions ( 17 ) . R-spondins are secreted ligands that can potentiate Wnt signaling in the presence of Wnt ligands ( 18 ) . Wnt signaling can also be activated via crosstalk with other signaling pathways, including the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway, where loss of PTEN can activate PKB/AKT, causing the phosphorylation and inactivation of GSK3B, which results in stabilization of β-catenin protein ( 19 ) . Growth factor signaling pathways can also activate Wnt signaling, such as in the RESEARCH ARTICLE case of stimulation of the EGF receptor (EGFR), which results in the activation of β-catenin/T-cell factor (TCF)/lymphoid enhancer factor (LEF)-dependent transcription of genes such as CyclinD1 ( CCND1 ), C-Myc ( MYC ), and Survivin ( BIRC5 ) ( 20, 21 ) . Notably, some human MPNSTs have been shown to have loss of PTEN expression and/or express high levels of active EGFR ( 9 , 11 , 12 , 14 ) . β-catenin-dependent transcription can promote progression through the cell cycle, stem cell self-renewal, and epithelial to mesenchymal transition, all of which play a role in tumor initiation and progression ( 15, 16 , 22 ) . Because of the importance of this pathway in driving tumorigenesis in many types of cancer, the development of small-molecule inhibitors that target Wnt signaling is rapidly underway and has the potential for profound clinical benefi ts for patients with Wnt-driven tumors ( 16 , 23 , 24 ) .
We have implicated canonical Wnt signaling in the development and progression of peripheral nerve tumors by using a murine Sleeping Beauty ( SB ) forward genetic screen (25) . In addition, we show that several well-established murine models of neurofi bromas and MPNST development also exhibit activation of the Wnt signaling pathway. Activation of this pathway has been confi rmed in human patient samples by gene expression microarray analysis and tissue microarray (TMA) studies. Activation of Wnt signaling occurs in human tumors through multiple mechanisms, including downregulation of β-catenin destruction complex members and overexpression of R-spondin 2 ( RSPO2 ). We show that activating canonical Wnt signaling is suffi cient to induce transformed properties in immortalized human Schwann cells in vitro . We also show that downregulating canonical Wnt signaling reduces the oncogenic and tumorigenic phenotypes observed in human NF1-associated and sporadic MPNST cell lines as measured by cell viability, colony formation, and xenograft tumor growth. Furthermore , we found that small-molecule inhibitors of Wnt signaling inhibit MPNST cell viability with little effect on normal human Schwann cells. These inhibitors show marked synergistic effects when combined with the mTOR inhibitor RAD-001, which has previously been shown to be moderately effective in preclinical MPNST models (26) (27) (28) . These results suggest that Wnt/β-catenin signaling is a novel drug target for patients with MPNSTs.
RESULTS

Diverse Mouse Models Implicate Canonical Wnt Signaling in Schwann Cell Tumor Development and Progression
To identify genes and pathways that drive Schwann cell tumor development and progression, a forward genetic screen using the SB transposon system was conducted in mice, similar to many that have been previously published ( 29 ) . The full details of this screen will be published separately (Rahrmann and colleagues, submitted for publication). This screen identifi ed several members of the canonical Wnt/β-catenin signaling pathway in the development of benign neurofi bromas and MPNSTs (Supplementary Table S1 ). This screen was conducted using a CNPase promoter driving Cre expression that, in combination with a Cre/Lox-regulated Rosa26-SB11 LSL transgene, allows for T2/Onc mutagenic transposon mobilization in Schwann cells and their precursors, the cell of origin for peripheral nerve sheath tumors ( 30 ) . A common transposon insertion site (CIS)-associated gene list was generated independently for benign neurofi bromas and MPNSTs, as diagnosed by histopathologic examination (Rahrmann and colleagues, submitted for publication). We required that integrations map uniquely to the murine genome with a sequence length that would preclude random mapping. Furthermore, we required that each integration be present at more than 1 of 10,000 of the total sequences present to exclude potential non-driver mutations that are found in minor subclones or due to artifacts ( 31 ) . When the entire CIS gene list for MPNSTs was analyzed using Ingenuity Pathway Analysis (Ingenuity Systems, www. ingenuity.com ), we found enrichment for genes that are present in the Wnt/β-catenin pathway ( P = 3.93E-4). Furthermore, when immunohistochemical (IHC) analysis was conducted on murine tumors from this SB screen at various stages of progression, the level and nuclear localization of β-catenin increased with tumor progression ( Fig. 1A ) . In addition to tumors from mice induced with SB , 4 other well-established mouse models of MPNST showed nuclear β-catenin expression ( Fig. 1B ; ; CNP-EGFR , stained very strongly for nuclear β-catenin, whereas the slower-forming NPcis and PLP-Cre; Nf1 fl /fl tumors had less total β-catenin, but still high nuclear staining. Thus, the intensity of nuclear β-catenin staining may correlate with and indeed drive tumor aggressiveness.
To determine the role of Wnt/β-catenin signaling in human Schwann cell tumors, we assayed the expression and localization of β-catenin and expression of known Wnt target genes in human Schwann cells and MPNST cell lines. Activated β-catenin is found in the nucleus where it can be transcriptionally active, whereas inactive β-catenin is cytoplasmically localized or membrane bound ( 22 ) . In a TERT/ CDK4 R24C immortalized human Schwann cell line (iHSC2λ; Margaret Wallace, manuscript in preparation), β-catenin was expressed, but localized primarily in the cytoplasm ( Fig. 1C ) . In contrast, both sporadic and NF1-associated MPNST cell lines (STS-26T and ST8814, respectively) expressed a similar level of β-catenin, but with predominantly nuclear localization. Western blot analysis showed that in all 4 MPNST cell lines analyzed, the level of MYC protein was increased, and in 2 of 4 MPNST cell lines, CCND1 protein was increased compared with the immortalized human Schwann cell line ( Fig. 1D ). These data suggest that known β-catenin outputs are increased in MPNST cell lines compared with immortalized human Schwann cells.
Canonical Wnt Signaling Is Activated in a Subset of Human Neurofi bromas and MPNSTs
To characterize whether alterations in regulators of Wnt signaling underlie pathway activation in MPNST cell lines, we assayed Wnt regulators by gene expression microarray in purifi ed Schwann cells taken from human peripheral nerve, neurofi bromas, and MPNSTs, as well as solid tumors at various stages of disease (ref. 35 ; Fig. 2 ). Several members of the β-catenin destruction complex, including APC and GSK3B , showed downregulation with tumor progression in a subset of cases. The Wnt ligand genes WNT2 , WNT5A and WNT5B RESEARCH ARTICLE Fig. 3A ). In addition, the percentage of tumors with nuclear β-catenin was higher in the MPNSTs than in the neurofi bromas ( Fig. 3B and C ) . As a transcriptional output of Wnt signaling, we also quantifi ed the percentage of CCND1-positive tumors and found that it A larger fraction of MPNSTs are CCND1-positive compared with the benign neurofi bromas and plexiform neurofi bromas. E, the level of CCND1 increases from benign neurofi bromas to plexiform neurofi bromas and is the greatest in MPNSTs. F, example of CCND1-staining intensity. G, a patient-matched plexiform neurofi broma, which transformed into an MPNST, shows higher total and nuclear β-catenin staining with transformation. The plexiform neurofi broma stained negative for CCND1, whereas the MPNST was CCND1 positive. 
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also increased in the higher-grade tumors (67.6% dNF, 64.7% pNF, 94.1% MPNST, P = 0.0051 Fisher's exact test; Fig. 3D ). Furthermore, the intensity of CCND1 staining increased with tumor progression ( P = 0.0356 Fisher's exact test; Fig.  3E and F ). As an additional transcriptional output of Wnt signaling, we assessed C-MYC staining intensity and found that it too showed a trend toward increased expression with tumor progression ( P = 0.1603 Fisher's exact test; Supplementary Fig. S1A and S1B). This suggests that the acquisition of nuclear β-catenin in these tumors is activating known β-catenin targets, and correlates with tumor progression. To confi rm this, we assessed β-catenin and CCND1 staining on a pNF that transformed into an MPNST. Although there was only a single patient represented on our TMA with a paired pNF and MPNST, we found that β-catenin level and nuclear localization increased in the MPNST. Furthermore, while the pNF was negative for CCND1, the MPNST was positive for CCND1 ( Fig. 3G ).
Activation of Wnt/b-catenin Signaling Is Suffi cient to Induce Transformed Phenotypes in Immortalized Schwann Cells
We next functionally validated a subset of the β-catenin-regulatory genes identifi ed in our SB screen that were also implicated in human tumors (Supplementary Table S1 and Fig. 2 ). We hypothesized that if Wnt/β-catenin signaling played a role in the development of peripheral nervous system tumors, then activation of this pathway in immortalized human Schwann cells may be suffi cient to drive a more transformed phenotype in these cells. To activate Wnt signaling, we expressed an activated form of CTNNB1 ( CTNNB1 S33Y ) in immortalized human Schwann cells (iHSC1λ and iHSC2λ). Cells overexpressing CTNNB1 S33Y showed increased levels of total β-catenin protein, but, interestingly, only the iHSC1λ cells showed increased activated β-catenin ( Fig. 4A ) . Expression of CTNNB1 S33Y resulted in increased expression of MYC , CCND1 , AXIN2 , LEF1 , and BIRC5 S33Y construct in the immortalized human Schwann cell line, iHSC1λ, results in an increase in total and activated β-catenin, whereas the expression in iHSC2λ cells results in only an increase in total β-catenin. B, expression of activated β-catenin increases cell viability in immortalized human Schwann cells. C, expression of CTNNB1 S33Y has no effect on soft agar colony formation in iHSC2λ cells. D, expression of CTNNB1 S33Y results in altered morphology when iHSC2λ cells are grown in 2-dimensional culture. E, the immortalized human Schwann cell line, iHSC2λ, has reduced AXIN1 and GSK3B transcript levels, respectively, when treated with short hairpin RNA constructs against these genes (AXIN 67 and GSK3B 90). F, knockdown of AXIN1 and GSK3B in iHSC2λ cells increases cell viability. G, reducing the expression of AXIN1 and GSK3B in iHSC2λ cells is suffi cient to increase soft agar colony formation. *, P < 0.05; **, P < 0.0001 unpaired t test. Error bars represent SEM. Fig. S2A and S2B ). CTNNB1 S33Y expression also resulted in increased cell viability ( Fig. 4B ), but did not change soft agar colony formation ( Fig. 4C ) . However, we did observe that cells overexpressing CTNNB1 S33Y stopped growing as a monolayer, as seen in nontransformed cells, and began growing as 3-dimensional colonies ( Fig. 4D ) .
In addition to activating Wnt signaling by overexpressing CTNNB1
S33Y
, we used short hairpin RNAs (shRNA) to knock down AXIN1 and GSK3B , both encoding members of the β-catenin destruction complex identifi ed in our SB screen (Supplementary Table S1 ) and known tumor suppressor genes in other types of cancers ( 15 ) . These genes were knocked down in both immortalized human Schwann cell lines (iHSC1λ and iHSC2λ) using shRNAs and validated by quantitative PCR (qPCR ) analysis ( S2C and S2F). We show that knockdown of either AXIN1 or GSK3B activated genes that have been shown to be to be targets of β-catenin, including CCND1 , MYC , AXIN2 , LEF1 , and BIRC5 ( Supplementary Fig. S2D , S2E, S2G, and S2H). Knockdown of AXIN1 or GSK3B was suffi cient to induce oncogenic properties in immortalized human Schwann cells as shown in vitro by a signifi cant increase in cell viability ( Fig. 4F and Supplementary Fig. S2J ) and anchorage-independent growth ( Fig. 4G and Supplementary Fig. S2K ). When the immortalized human Schwann cells that expressed either AXIN1 or GSK3B shRNAs were injected into immunodefi cient mice, they were unable to induce tumor formation (data not shown), suggesting that while activation of Wnt signaling is suffi cient to induce some oncogenic properties in Schwann cells in vitro , it is not suffi cient to induce tumorigenic properties in vivo.
Inhibition of Wnt Signaling Can Reduce the Tumorigenic Phenotype of MPNST Cells
We next sought to determine whether the inhibition of Wnt/β-catenin signaling in MPNST cell lines was suffi cient to reduce cellular viability and anchorage-independent growth. To reduce Wnt signaling, we knocked down CTNNB1 and TNKS in 2 MPNST cell lines, S462-TY (NF1-associated MPNST cell line; ref. 36 ) and STS-26T (sporadic MPNST cell line; ref. 37 ) using shRNA vectors. We chose to knockdown CTNNB1 , as it plays a direct role in the transcription of Wnt-dependent genes by binding TCF/LEF in the nucleus and acting as a transcriptional activator ( 22, 23 ) . TNKS was also knocked down because it was identifi ed in our forward genetic screen, and inhibition of TNKS is known to stabilize AXIN1, leading to the degradation of β-catenin protein ( 38 ) . TNKS is also the target of many small-molecule inhibitors of the Wnt pathway ( 38 ) . Knockdown of CTNNB1 and TNKS by shRNA was confi rmed by qPCR ( Fig. 5A and D ) . Reduction in either CTNNB1 or TNKS was suffi cient to decrease expression of β-catenin transcriptional targets, as shown by a reduction in the expression of MYC , CCND1 , AXIN2 , LEF1 , and BIRC5 ( Supplementary Fig. S3A-S3D ). Knockdown of either CTNNB1 or TNKS reduced cell viability ( Fig. 5B and E ) and anchorage-independent growth ( Fig. 5C and F ) in both S462-TY and STS-26T cells.
Overexpression of GSK3B , a member of the β-catenin destruction complex, was also suffi cient to reduce the oncogenic properties of both the NF1-associated and sporadic MPNST cell lines. GSK3B overexpression was confi rmed by Western blot analysis and qPCR and resulted in reduced β-catenin total protein levels ( Fig. 5G and Supplementary  Fig. S3E and S3F) . The reduction in known Wnt signaling outputs was also shown by a decrease in MYC , CCND1 , AXIN2 , LEF1 , and BIRC5 transcript levels ( Supplementary Fig.  S3E and S3F ). GSK3B overexpression resulted in a decrease in cell viability ( Fig. 5H ) and a signifi cant decrease in soft agar colony formation in both cell lines ( Fig. 5I ) . These results suggest that these MPNST cell lines depend on Wnt signaling for rapid proliferation and robust colony-forming abilities, and reduction in Wnt signaling can reduce these oncogenic properties.
To investigate the role of Wnt/β-catenin signaling in vivo , the S462-TY and STS-26T cell lines expressing either CTNNB1 shRNA or GSK3B cDNA were injected into immuno defi cient mice, which were monitored for the rate of tumor formation and growth. Reduction in CTNNB1 by shRNA delayed the rate of tumor growth in the NF1-asociated cell line ( Supplementary Fig. S4A and S4B ). Tumor sections derived from cells expressing the CTNNB1 shRNA showed fewer Ki67-positive cells compared with tumors derived from nonsilencing (NS) shRNA-expressing cells (Supplementary Fig. S4C ). Overexpression of GSK3B resulted in reduction in tumor growth in the spontaneous MPNST cell line ( Supplementary Fig. S4D and S4E ). Tumor sections from cells overexpressing GSK3B also showed fewer Ki67-positive cells compared with tumors derived from NS shRNA-expressing cells (Supplementary Fig. S4F ). Despite a signifi cant delay in tumor onset, tumor volume at 40 days after injection was similar in control and experimental groups. Evaluation of gene expression in these tumors indicated that knockdown of CTNNB1 and overexpression of GSK3B was not maintained over the course of the experiment (data not shown).
RSPO2 Is Overexpressed in a Subset of Schwann Cell Tumors and Is a Driver of Wnt Signaling and MPNST Cell Growth
R-spondins are secreted ligands that potentiate Wnt signaling when Wnt ligand is available ( 18 ) . Microarray analysis showed that RSPO2 was highly expressed in 2 of 6 MPNST cell lines and 2 of 13 primary MPNSTs evaluated compared with purifi ed normal human Schwann cells or normal nerve ( Fig. 6A ) . Furthermore, it has been shown that one mechanism for RSPO2 overexpression is a deletion-mediated gene fusion between exon 1 of EIF3E and exon 2 of RSPO2 , resulting in the overexpression of native RSPO2 protein ( 17 ) . To determine whether similar gene fusions occur in Schwann cell tumors, primers were designed to amplify any fusion transcripts between EIF3E and RSPO2 in cDNA libraries made from 5 human MPNST cell lines and 2 immortalized human Schwann cell lines. We identifi ed a fusion transcript expressed by the S462 MPNST cell line that was not present in any of the other MPNST or immortalized human Schwann cell lines ( Fig. 6B ) 
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RSPO2 expression in the S462 cell line ( Fig. 6C ) . The fusion transcript that was identifi ed included exon 1 of EIF3E fused to a 122 base pair region of chromosome 8 located between EIF3E and RSPO2 , fused to exon 2 of RSPO2 ( Fig. 6D ) . To determine whether S462 cells require RSPO2 , we used an shRNA construct to knock down its expression. Depletion of RSPO2 signifi cantly reduced expression of Wnt target genes and cell viability ( Fig. 6E and F ) . These data suggest that overexpression of RSPO2 may drive a subset of human MPNSTs, and further support the model that Wnt signaling is activated in Schwann cells by multiple mechanisms.
Wnt Inhibitors Effectively Reduce Cellular Viability In Vitro
Our functional data suggested that targeting Wnt/β-catenin signaling with small-molecule inhibitors might be effective at reducing MPNST cell viability and tumor forming properties. To test this hypothesis, we exposed a panel of 5 MPNST cell lines (S462, S462-TY, ST8814, T265, and STS-26T) and 2 immortalized human Schwann cell lines (iHSC1λ and iHSC2λ) to 2 compounds that inhibit Wnt signaling, XAV-939 and IWR-1. These compounds both function to stabilize AXIN1 by inhibiting TNKS, resulting in an increase in 
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β-catenin phosphorylation and subsequent degradation ( 38 ) . We found that normal Schwann cells are highly resistant to proliferation inhibition and cell death by these 2 compounds as shown by high IC 50 values, whereas the MPNST cell lines were quite sensitive with relatively low IC 50 s of 0.047 to 2.22 μmol/L for XAV-939 and 0.055 to 186.87 μmol/L for IWR-1 ( Fig. 7A ; CalcuSyn Version 2.1, BioSoft).
Wnt Inhibitors Synergize with an mTOR Inhibitor to Induce Apoptosis of MPNST Cells
We next conducted a screen to identify targeted therapies that synergized with Wnt signaling inhibitors to induce apoptosis in MPNST cell lines. Several drugs were screened, including inhibitors of PI3K (PI-103), mTOR (RAD-001 and rapamycin), and MEK (PD-901 and AZD-6244). Of these drugs, the most signifi cant synergism was seen with RAD-001. It has been shown that RAD-001 is modestly effective in several preclinical models of peripheral nerve tumors, but the effects of this drug are largely cytostatic ( 26, 27 ) . In most cases, treatment of the S462, T265, and STS-26T MPNST cell lines with RAD-001, IWR-1, or XAV-939 as single agents at their IC 50 concentrations resulted in less than 50% terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells, showing that although 50% Figure 6 . The secreted Wnt/β-catenin activator RSPO2 is highly expressed in a subset of human Schwann cell tumors and can be detected as a fusion transcript with the upstream EIF3E gene. A, gene expression microarray shows that a subset of plexiform neurofi bromas and MPNSTs from both purifi ed Schwann cells (top) and primary tumors (bottom) have high RSPO2 expression. B, cDNA libraries derived from human MPNST cell lines were screened for EIF3E-RSPO2 fusion transcripts (fusion transcripts verifi ed by sequencing are denoted by an arrow). C, fi ve MPNST cell lines were screened for RSPO2 expression levels and normalized to an immortalized human Schwann cell line (iHSC1λ). The S462 cell line showed very high RSPO2 expression and was found to contain a fusion between EIF3E and RSPO2 . D, the S462 cell line has a fusion between EIF3E exon 1, followed by a 122 base pair chromosome 8 intergenic sequence and RSPO2 exon 2. This fusion results in the production of a native RSPO2 protein. E, the S462 cell line was transduced with a lentivirus expressing an RSPO2 shRNA. This resulted in a decrease in RSPO2 expression, as well as a decrease in expression of known Wnt signaling outputs MYC , AXIN2 , LEF1 , CCND1 , and BIRC5 , as compared with S462 cells treated with a NS shRNA (NS GIPZ). F, knockdown of RSPO2 in S462 cells signifi cantly reduces cell viability. *, P < 0.05; **, P < 0.0001 unpaired t test. Error bars represent SEM. 
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of proliferation was inhibited, only a minority of cells underwent apoptosis ( Fig. 7B and C ) . In contrast, when the MPNST cell lines were treated with their IC 25 dose of RAD-001 in combination with either IWR-1 or XAV-939 also at their IC 25 dose, the percentage of TUNEL-positive cells often went above 50%, and in the S462 cell line, even approached 100%, showing that co-targeting the Wnt and mTOR pathways is synergistic in inducing apoptosis.
DISCUSSION
Analysis of MPNST tumor genomes has shown a wide variety of genetic changes ranging from point mutations to entire chromosome gains and losses ( 39 ) . Determining which of these changes contribute to tumorigenesis and which changes are simply "passenger" mutations is crucial in identifying targets for therapeutic intervention ( 1 , 39 , 40 ) . Prior studies have focused on NF1 and p53/Rb-regulated pathways in MPNSTs; yet, there remains a need to broaden our understanding of the genetic alterations that contribute to Schwann cell tumorigenesis. The SB transposon system is an unbiased, powerful tool to identify oncogenes and tumor suppressor genes ( 29 ) . In an SB screen conducted to fi nd genetic drivers of MPNSTs and neurofi bromas, we uncovered many alterations that affect canonical Wnt/β-catenin signaling, suggesting this pathway is a likely driver of Schwann cell tumor development, progression, and maintenance (Supplementary Table S1 ) (25) . We showed that murine tumors from both the SB screen and from 4 other established MPNST models showed nuclear-localized β-catenin, suggesting that 
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they have activated canonical Wnt signaling ( Fig. 1 ) . In addition, we identifi ed activation of Wnt signaling in a majority of human MPNST cell lines and primary human tumors investigated ( Figs. 1-3 ) .
In this study, we showed that multiple genetic alterations correlate with activation of the canonical Wnt/β-catenin pathway, and that these alterations can induce oncogenic properties in human Schwann cells and are required for tumor maintenance in MPNST cells. A subset of human Schwann cell tumors shows downregulation of β-catenin destruction complex components, such as APC and GSK3B ( Fig. 2 ) . Microarray analysis also showed overexpression of several Wnt ligands and RSPO2 , a secreted ligand that can potentiate Wnt signaling, in a subset of human tumors ( Fig. 6 ) . Interestingly, we found that while CCND1 protein levels correlate with tumor progression, CCND1 mRNA expression is not as convincing ( Figs. 2 and 3 ) . It should be noted that the microarray data suggest that in whole tumors, CCND1 may be decreased, but in purifi ed cells, it seems to be unchanged or slightly upregulated. This may be due to the effects of contaminating cells within the whole tumor, such as fi broblasts, macrophages, and endothelial cells. In addition, we believe that the discrepancy seen between the TMA and the microarray gene expression of CCND1 may be due to the fact that the CCND1 transcript is highly regulated at the translational level. Because of the long 5′ untranslated region and secondary structure of CCND1 mRNA, it is often poorly translated, although many factors, including PI3K/mTOR signaling, can increase the translation of this transcript ( 41 ) . On the basis of the mRNA expression data, MYC may be a more consistent marker for activated Wnt signaling, whereas CCND1 may be a better marker of Wnt signaling activation by IHC.
We tested the functional importance of Wnt pathway activation in Schwann cell tumorigenesis through gain-and loss-of-function studies in vitro. Using gene overexpression and knockdown in immortalized human Schwann cells and MPNST cell lines, we showed that aberrant expression of Wnt regulators resulted in phenotypic and functional changes in these cells. Downregulation of GSK3B and AXIN1 and overexpression of CTNNB1 were suffi cient to induce transformed properties in immortalized human Schwann cells, and downregulation of CTNNB1 and TNKS , as well as overexpression of GSK3B , reduced the oncogenic properties of MPNST cell lines and delayed tumor growth in vivo ( Figs. 4 and 5 and Supplementary Figs. S2 and S4) .
Recently, a novel mechanism for activating Wnt signaling was shown in colorectal cancer in which gene fusions occurred between EIF3E and RSPO2 due to a deletion on chromosome 8, resulting in the overexpression of native RSPO2 protein ( 17 ) . We identifi ed a similar fusion transcript in a human MPNST cell line with elevated RSPO2 expression and showed that knockdown of RSPO2 was suffi cient to reduce Wnt signaling outputs and cellular viability in this cell line ( Fig. 6 ) . Further work is needed to determine the frequency of R-spondin fusion transcript expression in primary human Schwann cell tumors. It will also be necessary to identify whether expression of R-spondin fusion transcripts in MPNSTs is mediated by chromosome 8 deletions similar to those seen in colorectal cancer, or if there is another mechanism by which this occurs, such as transcription-mediated gene fusion. On the basis of our results, a drug that could block the function of RSPO2 may be therapeutically beneficial for patients with MPNSTs overexpressing RSPO2 .
In addition to the mechanisms described above, there are likely other mechanisms by which this pathway is activated in human tumors. For example, activation of PKB/AKT, a common phenomenon in MPNSTs, leads to the phosphorylation and inactivation of GSK3β, resulting in stabilization of the β-catenin protein ( 19 , 42 ) . Loss of PTEN expression has been shown in human MPNSTs, and this could activate Wnt signaling through activation of AKT ( 12, 13 ) . It has also been shown that in cells expressing EGFR, EGF stimulation can result in the activation of β-catenin/TCF/LEF-dependent transcription, and EGFR expression has been implicated in MPNST development as well ( 9 , 11 , 20 ) . Recently, Mo and colleagues ( 43 ) showed a novel mechanism of NF1-associated MPNST progression in which autocrine activation of CXCR4 by CXCL12 mediates tumor progression through PI3K and β-catenin. Although no insertions were identifi ed in Cxcr4 or Cxcl12 in our SB screen, gene expression data from human tumors showed statistically signifi cant differential regulation of CXCR4 in MPNST tumor-to-nerve comparison (fc = 5.3×, P = 0.016), but not in MPNST cell-to-NHSC comparison (fc = 0.85×, P = 0.16). In contrast, CXCL12 showed a statistically differential expression pattern in MPNST cell-to-NHSC comparison (fc = 2.7×, P = 0.02), but not in MPNST tumorto-nerve comparison (fc = 4.7×, P = 0.15). This study by Mo and colleagues ( 43 ) complements our work in showing yet another mechanism by which human Schwann cell-derived tumors activate Wnt signaling, leading to tumor progression. Additional work will be required to determine the contribution of each of these pathways to Wnt activation in human MPNSTs.
It is unclear from this study whether Wnt pathway activation is important for tumor initiation or for tumor progression, but it seems likely that it may play a role in both processes. It is clear that a subset of benign human neurofi bromas exhibit activated Wnt signaling, which may play a role in the initiation of these benign tumors ( Fig. 3 and Supplementary Fig. S1 ). A larger percentage of high-grade tumors (MPNSTs) have activation of this signaling pathway, making it plausible that this pathway also plays a role in progression from a benign tumor to malignancy. It is also likely that this pathway may cooperate with other pathways that play a role in the development or progression of MPNSTs. For example, Wnt signaling activation is an initiating event for colorectal cancer, leading to hyperplasia, but other genetic changes must occur for a tumor to form ( 44 ) . Future work will need to focus on identifying cooperating mutations or signaling pathways that function in concert with Wnt signaling in MPNST formation. Indeed, loss of NF1 expression is a good candidate for cooperating alteration, and future experiments in which NF1 is lost and the Wnt pathway is activated in normal Schwann cells will be critical to our understanding of cooperating genes and pathways.
Although the Wnt pathway is known to play a critical role in oncogenesis, the development of clinically benefi cial targeted therapies has lagged. The discovery of small-molecule inhibitors of the Wnt/β-catenin pathway is being aggressively 
pursued, as these therapies have the potential to benefi t patients suffering from a wide variety of cancers ( 16 , 23 , 24 ) . Wnt/β-catenin signaling is critical for many normal developmental and cellular processes; thus, inhibition of this pathway may have many unwanted and negative side effects ( 16 , 45 ) . To this end, inhibitors targeting specifi c Wnt pathway molecules (such as RSPO2) and functions in tumorigenesis may be the key to identifying a successful targeted therapy ( 16 , 45 ) . We show that inhibiting Wnt signaling in vitro is an effective cytostatic therapy, but when combined with RAD-001, it creates a potent cytotoxic therapy ( Fig. 7 ) . Further work will need to be done to investigate the use of Wnt pathway inhibitors using in vivo models of MPNST, as these may be a valuable new class of targeted therapies for patients with MPNSTs.
METHODS
Mouse Tumor Immunohistochemistry
Formalin-fi xed, paraffi n-embedded tissues were sectioned at 5 μm, mounted, and heat-fi xed onto glass slides to be used for IHC analyses. Briefl y, the glass section slides were dewaxed and rehydrated through a gradual decrease in ethanol concentration. The antigen epitopes on the tissue sections were then unmasked using a commercially available unmasking solution (Vector Laboratories) according to the manufacturer's instructions. The tissue section slides were then treated with 3% hydrogen peroxide to remove endogenous peroxidases. Blocking was conducted at room temperature in normal goat serum (5% serum in PBS) in a humidifi ed chamber for one hour. Sections were then incubated overnight at 4°C in a humidifi ed chamber with primary antibody (β-catenin, 1:100, Cell Signaling). After primary incubation, sections were washed thoroughly in PBS before incubating with goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology). After 3 washes with PBS, the sections were treated with freshly prepared 3,3′-diaminobenzidine substrate (Vector Laboratories) and allowed to develop before stopping the reaction in water once adequate signal was obtained. Finally, sections were then lightly counter-stained with hematoxylin, dehydrated through gradual increase in ethanol concentration, cleared in Citrosol (Fisher Scientifi c), and mounted in Permount (Fisher Scientifi c).
Tissue Culture Reagents and Cell Lines
Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C to allow in vitro studies (Dr. Margaret Wallace, manuscript in preparation). 
Immunofl uorescence and TUNEL Staining
For immunofl uorescence assays, cells were grown to 80% confl uency on 8 chambered slides (Lab-TekII). Cells were fi xed in 10% formalin and washed with PBS with 0.1% Tween-20. Cells were incubated in β-catenin primary antibody (1:100, Cell Signaling) at 4°C overnight, followed by 1-hour room temperature incubation in anti-rabbit AlexaFluor 488 secondary antibody (Invitrogen). TUNEL staining was conducted using the In Situ Cell Death Detection Kit, POD (Roche). Slides were mounted using Prolong Gold Antifade Reagent with 4′, 6-diamidino-2-phenylindole (DAPI; Invitrogen) and images using a Zeiss Axiovert 25 inverted microscope. For analysis of cell death, total cells and TUNEL-positive cells were counted and averaged over 3 independent frames with 50 to 100 cells per frame.
Western Blot Analysis
One million cells were lysed using an NP-40 buffer (50 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl, 1% NP-40, 5 mmol/L NaF, 1 mmol/L EDTA) containing a protease inhibitor (Roche) and phosphatase inhibitors (Sigma). Whole-cell lysates were cleared by centrifugation. Protein samples were prepared in an SDS solution with reducing agent (Invitrogen) and run on 10% Bis-Tris pre-made gels (NuPage, Invitrogen). Gels were transferred onto polyvinylidene di fl uoride membranes using the iBlot system (Invitrogen) and activated in 100% methanol. Membranes were blocked in fi ltered 5% bovine serum albumin (BSA) for 2 hours at room temperature, followed by a 4°C overnight incubation in primary antibody. The primary antibodies used in this study were activated β-catenin (1:1,000), total β-catenin (1:100), GSK3B (1:1,000), AXIN1 (1:1,000), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:2,000; Cell Signaling). Following primary antibody incubation, membranes were thoroughly washed in TBS with 0.1% Tween-20 (TBST) and incubated in goat anti-rabbit IgG-HRP-conjugated secondary antibody (Santa Cruz, 1:4,000 in 0.5% BSA, 1 hour at room temperature). Blots were thoroughly washed in TBST and developed using the SuperSignal WestPico Chemiluminescence Detection Kit (Thermo Scientifi c). Densitometry quantifi cation was done using ImageJ software and normalized to GAPDH ( 49 ) .
Microarray Gene Expression Analysis
We used the published data (GEO accession GSE14038, Affymetrix GeneChip HU133 Plus 2.0; ref. 39 ) for gene microarray analysis. This dataset used custom CDF (custom GeneChip library fi le) based on RefSeq target defi nitions (Hs133P RefSeq Version 8) for accurate interpretation of GeneChip data ( 50 ) . The dataset in Fig. 2 includes 86 microarrays on purifi ed human Schwann cells and primary tissues taken from a normal sciatic nerve, dNFs, pNFs, and MPNST cell lines. The heatmap was generated using CRAN's pheatmap package ( http://cran.r-project.org/web/packages/pheatmap/index.html ), and Refseq IDs were replaced with corresponding HUGO Gene Nomenclature Committee offi cial gene symbols. Statistical comparisons were done using R/Bioconductor's Limma package ( http://www.bioconductor.org ) and GeneSpring GXv7.3.1 (Agilent Technologies). Differentially expressed genes were defi ned as genes with expression levels at least 3-fold higher or lower in target groups (MPNST) compared with NHSC after applying Benjamini and Hochberg false discovery rate correction ( P ≤ 0.05).
Tissue Microarray Construction and Immunohistochemistry
Representative areas of disease were identifi ed on hematoxylin and eosin-stained sections for 30 neurofi bromas, 32 plexiform neurofi bromas, and 31 MPNSTs. TMA blocks consisting of duplicate 1.0 mm core samples were constructed with a manual tissue arrayer (MTA-1, Beecher Inc) and limited to 64 cores per recipient block. IHC for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientifi c, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200) was conducted using an automated IHC staining platform (Nemesis 7200, Biocare) following standard IHC protocols ( 51 ) . Digital images of IHC-stained TMA slides were obtained as previously described by Rizzardi and colleagues ( 52 ) . P values were determined using a 3 × 2 (staining positivity) or 3 × 3 (staining intensity or localization) Fisher's exact test to determine differences in staining between the 3 tumor types. 
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Gene Knockdown and Overexpression
GSK3B and Luciferase cDNA (Invitrogen) were each cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP. These plasmid vectors were transfected into cells using the NEON transfection system, according to the manufacturer's protocol (Invitrogen). Three independent shRNAs targeting AXIN1 , GSK3B , CTNNB1 , TNKS , RSPO2 , and a non-silencing control shRNA were purchased from OpenBiosystems. Lentiviral particles containing the shRNAs were produced in 293T cells using the TransLentiviral Packaging Kit (Thermo Scientifi c). A dsRed control and CTNNB1 S33Y were cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP and also transduced into cells using lentiviral particles. Viral supernatant was collected after 24 hours of viral production, cleared, and applied directly to the cells for 6 hours. Following viral transduction, cells underwent selection in 4 μg/mL puromycin (Invitrogen). shRNA expression was validated by GFP expression, Western blot analysis, and qPCR. Data are shown for the one shRNA construct that gave the greatest knockdown as determined by Western blot analysis and/or qPCR.
Quantitative PCR
RNA was extracted from 1 million cells using the High Pure RNA Isolation Kit (Roche). RNA was analyzed by nanodrop (Thermo Scientifi c) and by agarose gel electrophoresis for quantifi cation and quality control. One μg of RNA was used to synthesize cDNA using the Transcriptor First Strand Synthesis (Roche) with both random hexamer and oligo dT primers. qPCR reactions were conducted using LightCycler 480 SYBR I Green (Roche) and run on an Eppendorf Mastercycler ep gradient S. Primer sequences can be found in Supplementary Table S2 ( 21 , 53 , 54 ) . Data were analyzed using RealPlex software, calibrated to ACTB levels and normalized to either overexpression control cells (expressing CAGGS > Luciferase-IRES-GFP or dsRed) or non-silencing shRNA-expressing cells and averaged over 3 experimental replicates.
Cellular Viability Assays
Cellular viability assays were set up in a 96-well format with 100 cells plated per well in DMEM full media containing 4 μg/mL puromycin (Invitrogen). Readings were taken every 24 hours over 6 days by the MTS assay (Promega). Absorbance was read at 490 nm to determine viability and 650 nm to account for cellular debris on a BioTek Synergy Mx automated plate reader.
Anchorage-Independent Growth Assay
Six-well plates were prepared with bottom agar composed of 3.2% SeaPlaque Agar (Lonza) in DMEM full media and allowed to solidify before 10,000 cells in top agar (0.8% SeaPlaque Agar in DMEM full media) were plated and allowed to solidify. DMEM full media with 4 μg/mL puromycin (Invitrogen) was plated over the cells and cells were incubated under standard conditions (5% CO 2 , 37°C) for 14 days. Top media were removed and cells were fi xed in 10% formalin (Fisher Scientifi c) containing 0.005% crystal violet (Sigma) for 1 hour at room temperature. Formalin was removed and colonies were imaged on a Leica S8 AP0 microscope. Twelve images per cell line were taken and automated colony counts were done using ImageJ software ( 49 ) . Results shown are a representative example of at least 3 independent experiments.
Xenografts
A total of 1.5 million cells in serum-free DMEM with 33% Matrigel Basement Membrane (BD Biosciences) were injected into the back fl anks of athymic Foxn1 nu/nu mice (Charles River Laboratories). Each mouse was injected on the right fl ank with cells expressing a specifi c shRNA or a cDNA and on the left fl ank with control cell lines expressing a non-silencing shRNA or a Luciferase cDNA with at least 4 mice per experiment. Tumor volume was measured biweekly using calipers, and mice were sacrifi ced when the tumor reached approximately 10% of the total body weight or 40 days after injection. Tumors were harvested for IHC and Western blot analysis. All animal work was conducted according to the University of Minnesota's approved animal welfare protocol.
In Vitro Drug Studies to Determine IC 50 RAD-001, IWR-1, and XAV-939 were solubilized in dimethyl sulf oxide and then subsequently diluted in sterile PBS. A total of 1,200 cells per well of a 96-well plate were treated with varying concentration of drug in quadruplicate and assayed for cell viability using the MTS assay (Promega) to determine the IC 50 values. All data analysis was done using CalcuSyn software (CalcuSyn Version 2.1, BioSoft). 
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